Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

PCW-1001, a novel pyrazole compound, modulates the expression of DNA damage response genes

ABSTRACT: PCW-1001, a novel pyrazole compound, modulates the expression of DNA damage response genes

PROVIDER: PRJNA788874 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

PCW-1001, a novel pyrazole compound, modulates the expression of DNA damage response genes

Project description:As pyrazole and its derivatives have a wide range of biological activities, including anticancer activity, the design of novel pyrazole derivatives has emerged as an important research field. This study describes a novel pyrazole derivative that exerts antitumor and radiosensitizing activities in breast cancer both in vitro and in vivo. We synthesized a novel pyrazole compound N,N-dimethyl-N'-(3-(1-(4-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)phenyl)azanesulfonamide (PCW-1001) and showed that it inhibited several oncogenic properties of breast cancer both in vitro and in vivo. PCW-1001 induced apoptosis in several breast cancer cell lines. Transcriptome analysis of PCW-1001-treated cells showed that it regulated the DNA damage response, suggesting its potential use in radiotherapy. Indeed, PCW-1001 enhanced the radiation sensitivity of breast cancer cells by modulating the expression of DNA damage response genes. Therefore, our data describe a novel pyrazole compound, PCW-1001, with antitumor and radiosensitizer activities in breast cancer.

2021-12-15 | GSE190883 | GEO

ORY-1001/RG6016 effect on leukemia cell lines

Project description:The lysine-specific demethylase LSD1/KDM1A is a key regulator of stem cell potential in acute myeloid leukemia (AML). Inhibition of its expression or catalytic activity overcomes the differentiation block and reduces colony formation potential. We have developed ORY-1001 as highly potent and selective inhibitor of KDM1A. Treatment of AML cell lines with ORY-1001 induces accumulation of H3K4me2 marks at KDM1A target genes, compromises leukemic stem cell capacity, and provokes blast differentiation. ORY-1001 exhibits potent synergy with standard of care drugs and with inhibitors of other epigenetic targets; reduces tumor growth and extends survival in mouse xenograft models of acute leukemia. To develop tools for use in clinical trials, we selected a panel of surrogate biomarkers for pharmacodynamic analysis based on expression changes in a panel of 24 leukemia cell lines. ORY-1001/RG6016 was the first selective KDM1A inhibitor to enter the clinic and is currently being evaluated in leukemia and solid tumor clinical trials.

2018-08-19 | GSE94567 | GEO

Effect of LSD1 Inhibitor ORY-1001 on NCI-H1876 small cell lung cancer cells that are CRISPR-inactivated for ZFP36L1 (sgZFP36L1) or ZFP36L1-WT (sgControl)

Project description:To investigate the impact of inactivating ZFP36L1 on the transcriptional response to the LSD1 inhibitor ORY-1001 We performed RNA-sequencing on NCI-H1876 sgZFP36L1 or sgControl cells treated with ORY-1001 or DMSO

2022-05-06 | GSE202112 | GEO

Circadian Cryptochrome 1 (CRY1) Rhythmically Modulates the DNA Damage Response

Project description:Circadian Cryptochrome 1 (CRY1) Rhythmically Modulates the DNA Damage Response

| PRJNA605447 | ENA

Panicum virgatum cultivar:1001

Project description:Panicum virgatum exome capture - 1001

| PRJNA447415 | ENA

clavispora lusitaniae MTCC 1001

Project description:clavispora lusitaniae MTCC 1001 Genome sequencing and assembly

| PRJNA195921 | ENA

Circadian Cryptochrome 1 (CRY1) Rhythmically Modulates the DNA Damage Response [ChIP-seq]

Project description:Circadian Cryptochrome 1 (CRY1) Rhythmically Modulates the DNA Damage Response [ChIP-seq]

| PRJNA605455 | ENA

Circadian Cryptochrome 1 (CRY1) Rhythmically Modulates the DNA Damage Response [RNA-seq]

Project description:Circadian Cryptochrome 1 (CRY1) Rhythmically Modulates the DNA Damage Response [RNA-seq]

| PRJNA605454 | ENA

Pichia kudriavzevii strain:KCKM 1001

Project description:Pichia kudriavzevii strain:KCKM 1001 Genome sequencing and assembly

| PRJNA767192 | ENA

Organoid phenotypic testing identifies IFN-beta as neuroprotective compound against ZIKA virus (ZIKV)

Project description:Administration of recombinant interferons to 3D brain organoid cultures infected with ZIKV identifies IFN-beta as compound that alleviates organoid damage and inhibits ZIKV

2021-04-09 | GSE123816 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data